S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

$0.47
+0.01 (+2.44%)
(As of 01:03 PM ET)
Today's Range
$0.45
$0.49
50-Day Range
$0.44
$0.69
52-Week Range
$0.41
$3.28
Volume
83,243 shs
Average Volume
111,532 shs
Market Capitalization
$8.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Trevena MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,070.7% Upside
$5.50 Price Target
Short Interest
Healthy
0.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.59) to ($1.73) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.70 out of 5 stars

TRVN stock logo

About Trevena Stock (NASDAQ:TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

TRVN Stock Price History

TRVN Stock News Headlines

Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Trevena Stock (NASDAQ:TRVN), Short Interest Report
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Trevena Awarded OLINVYK Agreement with Premier, Inc.
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Trevena (NASDAQ: TRVN)
Trevena Shares Rise 18% After Getting $15M Tranche
See More Headlines
Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2023
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRVN
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$9.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,099.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,670,000.00
Pretax Margin
-949.98%

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$2.25 per share

Miscellaneous

Free Float
17,881,000
Market Cap
$8.40 million
Optionable
Optionable
Beta
1.13
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Carrie L. BourdowMs. Carrie L. Bourdow (Age 61)
    President, CEO & Chairman
    Comp: $1M
  • Mr. Barry Shin (Age 51)
    Executive VP, COO & CFO
    Comp: $670.02k
  • Dr. Mark A. Demitrack M.D. (Age 65)
    Senior VP & Chief Medical Officer
    Comp: $690.32k
  • Dr. Howard A. Rockman M.D.
    Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Joel Solomon
    VP, General Counsel & Chief Compliance Officer
  • Mr. Michael Catalano
    Vice President of Marketing
  • Mr. Robert T. Yoder (Age 58)
    Senior VP, Chief Business Officer & Head of Commercial Operations
    Comp: $490.64k
  • Ms. Patricia M. Drake (Age 58)
    Senior VP & Chief Commercial Officer

TRVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevena stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings
or view top-rated stocks.

What is Trevena's stock price target for 2024?

2 Wall Street analysts have issued 12-month target prices for Trevena's stock. Their TRVN share price targets range from $2.00 to $9.00. On average, they anticipate the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,070.7% from the stock's current price.
View analysts price targets for TRVN
or view top-rated stocks among Wall Street analysts.

How have TRVN shares performed in 2024?

Trevena's stock was trading at $0.7221 at the beginning of 2024. Since then, TRVN shares have decreased by 34.9% and is now trading at $0.4698.
View the best growth stocks for 2024 here
.

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our TRVN earnings forecast
.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) announced its earnings results on Monday, May, 15th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The biopharmaceutical company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.60 million. During the same quarter in the prior year, the firm earned ($2.50) earnings per share.

When did Trevena's stock split?

Trevena shares reverse split on Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Trevena own?
Who are Trevena's major shareholders?

Trevena's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.61%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow.
View institutional ownership trends
.

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners